Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
4,619 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.
Cordas Dos Santos DM, Tix T, Shouval R, et al. · Nat Med · 2024Systematic Review, Meta-Analysis
- Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
Reynolds G, Cliff ERS, Mohyuddin GR, et al. · Blood Adv · 2023Meta-Analysis, Systematic Review
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.
Tix T, Alhomoud M, Shouval R, et al. · Mol Ther · 2025Systematic Review, Meta-Analysis
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.
Martino EA, Caridà G, Lofaro D, et al. · ESMO Open · 2025Network Meta-Analysis, Systematic Review
- Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis.
Richter J, Nooka A, Rodríguez-Otero P, et al. · Am J Hematol · 2025Systematic Review, Comparative Study
- Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.
Kaiser MF, Sonneveld P, Cairns DA, et al. · J Clin Oncol · 2025Systematic Review, Meta-Analysis
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC, Avet-Loiseau H, Anderson KC, et al. · Blood Adv · 2020Meta-Analysis, Research Support, N.I.H., Extramural
- Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.
Beer SA, Cairns DA, Pawlyn C, et al. · Blood · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T, Hübel K, Monsef I, et al. · Cochrane Database Syst Rev · 2015Meta-Analysis, Research Support, Non-U.S. Gov't
- The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).
Ludwig H, Terpos E, Gay F, et al. · Am J Hematol · 2026Systematic Review, Network Meta-Analysis
- Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
Li Q, Ai L, Zuo L, et al. · Ann Med · 2024Meta-Analysis, Systematic Review
- Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.
Richardson P, Beksaç M, Oriol A, et al. · Eur J Haematol · 2025Clinical Trial, Phase III, Multicenter Study
- Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.
Souto Filho JTD, Cantadori LO, Crusoe EQ, et al. · Blood Cancer J · 2025Meta-Analysis, Network Meta-Analysis
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.
Quan L, Li Q, Ma C, et al. · Ann Med · 2025Systematic Review, Meta-Analysis
- Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
Balmaceda N, Aziz M, Chandrasekar VT, et al. · BMC Cancer · 2021Historical Article, Meta-Analysis
- Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis.
Chong LL, Soon YY, Soekojo CY, et al. · Crit Rev Oncol Hematol · 2021Meta-Analysis, Systematic Review
- Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis.
Rose CJ, Ohm IK, Giske L, et al. · BMJ Open · 2023Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis.
Ling Y, Li R, Zhong J, et al. · Drug Chem Toxicol · 2022Meta-Analysis, Systematic Review
- Interferon therapy in myelomatosis.
Mellstedt H, Ahre A, Björkholm M, et al. · Lancet · 1979Case Reports, Clinical Trial
- Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis.
Koshiaris C, Oke J, Abel L, et al. · BMJ Open · 2018Meta-Analysis, Research Support, Non-U.S. Gov't
- The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis.
Jiang Y, Zhang C, Lu L, et al. · Technol Cancer Res Treat · 2022Meta-Analysis, Research Support, Non-U.S. Gov't
- Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Ebraheem MS, Chakraborty R, Rochwerg B, et al. · Blood Adv · 2024Systematic Review, Meta-Analysis
- Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
Minakata D, Fujiwara SI, Yokoyama D, et al. · Br J Haematol · 2023Systematic Review, Network Meta-Analysis
- Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis.
Mohyuddin GR, Aziz M, McClune B, et al. · Eur J Haematol · 2020Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.